The University of Kansas Health System has launched a new robotic heart program featuring the Genesis robotic magnetic navigation (RMN) system developed by Stereotaxis Inc. This initiative aims to enhance cardiac care by utilizing advanced robotic technology for treating arrhythmias through cardiac ablation.
Last week, physicians at the health system successfully performed procedures using the Genesis system, marking a significant milestone in the program. The Genesis RMN system is designed to provide precise and safe navigation during complex cardiac procedures, improving both accuracy and patient outcomes.
Dr. Seth Sheldon, a cardiac electrophysiologist at the University of Kansas Health System, emphasized the importance of robotic technology in delivering superior patient care. “For years, advanced robot technology has been instrumental in our ability to navigate complex cardiac procedures with improved accuracy and safety,” he stated. He added that the Genesis system allows for personalized treatments, ultimately enhancing patients’ quality of life.
The Genesis system features smaller magnets that rotate around their center of mass, which enhances responsiveness to physician control. This compact design not only improves the patient experience but also increases accessibility and maximizes lab space. The system’s flexible robotic arms allow for a greater range of motion and wider X-ray angulation during procedures.
Stereotaxis has previously seen success with its Genesis surgical robot at a Kentucky hospital, which performed its first procedures late last year. The company is also collaborating with Abbott on various developments in cardiac care.
David Fischel, chairman and CEO of Stereotaxis, expressed pride in partnering with the University of Kansas Health System to deliver exceptional cardiac care. He stated, “We look forward to continuing to support their successful and impactful robotic heart-rhythm care program.”
In August, Stereotaxis submitted its next-generation GenesisX system for approval from the U.S. Food and Drug Administration (FDA), following its receipt of the CE mark in Europe. The company reports that its technology has been utilized to treat over 150,000 patients worldwide.
Stereotaxis has been recognized as one of the top surgical robotics companies to watch in 2024 by MassDevice, highlighting its innovative contributions to the field of robotic-assisted cardiac procedures.
Related topics:
- Johnson & Johnson’s Heart Device Receives FDA Approval for Abnormal Rhythm Treatment
- Cardiac Arrhythmia Leads to Withdrawal of Athabascan from Melbourne Cup
- Medtronic Gains FDA Approval for New Mapping And Ablation System